Related Experiment Videos
1995 Gaston Labat Lecture. Ropivacaine. White knight or dark horse?
1Department of Anesthesiology, University of South Carolina, Richland Memorial Hospital, Columbia, USA.
Regional Anesthesia
|November 1, 1995
Summary
Ropivacaine, a new local anesthetic, offers reduced cardiotoxicity compared to bupivacaine due to its specific stereoisomer. This advancement promises safer regional anesthesia and potential applications in obstetric and ambulatory settings.
Area of Science:
- Anesthesiology
- Pharmacology
- Stereochemistry
Background:
- Local anesthetics like bupivacaine can cause cardiotoxicity due to the R-stereoisomer's prolonged sodium channel interaction.
- Chirality in local anesthetics leads to different receptor kinetics between S- and R-stereoisomers.
Purpose of the Study:
- To review the stereoselectivity of bupivacaine isomers and the evaluation of ropivacaine.
- To prepare North American clinicians for ropivacaine's introduction by summarizing basic and clinical findings.
- To explore potential clinical applications of ropivacaine.
Main Methods:
- Literature survey on bupivacaine isomer stereoselectivity and ropivacaine evaluation.
- Inclusion of a stereoisomerism primer for non-scientists.
Main Results:
- Ropivacaine is synthesized as a pure S-monomer, unlike racemic bupivacaine.
- Ropivacaine exhibits lower cardiotoxic potential than racemic bupivacaine.
Conclusions:
- Ropivacaine's S-monomer form reduces cardiotoxicity associated with the R-isomer of bupivacaine.
- Potential applications include obstetric analgesia and ambulatory anesthesia due to its profile.